Journal
VACCINE
Volume 39, Issue 44, Pages 6454-6459Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.09.057
Keywords
COVID-19; Vaccine hesitancy; Vaccine acceptance; Immune-mediated inflammatory diseases
Categories
Ask authors/readers for more resources
In adults with immune-mediated inflammatory diseases (IMID), factors such as concurrent malignancy, fibromyalgia, hydroxychloroquine use, and recent corticosteroid pulse therapy were found to be associated with higher odds of COVID-19 vaccine hesitancy. The study highlights the need for greater awareness on the safety and efficacy of COVID-19 vaccines among both IMID patients and attending physicians.
Objectives: To identify potential predictors of COVID-19 vaccine hesitancy (C19-VH) in adults with immune-mediated inflammatory diseases (IMID). Methods: A total of 1000 IMID patients were enrolled in this web-based cross-sectional study. A standardised and self-administered survey was designed by members of the Brazilian Society of Rheumatology Steering Committee for Infectious and Endemic diseases and distributed to IMID patients spread across Brazil. Results: Of the 908 (90.8%) respondents eligible for analysis, 744 (81.9%) were willing to get vaccinated against COVID-19. In our multivariable logistic regression model, concurrent malignancy, fibromyalgia, hydroxychloroquine use, and recent corticosteroid pulse therapy were independently associated with higher odds of C19-VH. The short duration of COVID-19 vaccine clinical trials was the main reason for C19-VH. Conclusion: We identified novel characteristics potentially associated with C19-VH among adults with IMID. Greater awareness on the safety and efficacy of COVID-19 vaccines is needed for both IMID patients and attending physicians. (c) 2021 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available